Loading...
Loading...
VTYX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 42.6M |
| Operating I/L | -42.6M |
| Other Income/Expense | 3.6M |
| Interest Income | 3.6M |
| Pretax | -38.9M |
| Income Tax Expense | -3.6M |
| Net Income/Loss | -35.3M |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the development of small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate, VTX958, is a tyrosine kinase type 2 inhibitor in phase I clinical trials for immune-mediated diseases such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Additionally, the company is developing VTX002, an oral sphingosine 1 phosphate receptor 1 modulator, and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases. Ventyx Biosciences, Inc. also focuses on developing CNS-penetrant NLRP3 inhibitors for neurodegenerative diseases.
